StockData
Entera Bio Ltd. logo

Entera Bio Ltd. (ENTX) shareholders

ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$3.00−0.02 (-0.66%)

Close on Nov 17, 2026Market cap $519.43MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
6.2%
11M of 173M shares
Institutional holders
27
7 new, 6 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
8 buys · 0 sales
Net bought $140.88K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Lampert Mark N
Joint filing with Bvf Partners L P/Il (9.99%), Bvf Inc/Il (9.99%) and 3 more
17,225,1219.99%13D (active)Jul 28, 2026
Chen Yu
Joint filing with TCG Crossover GP III, LLC (7.10%), TCG Crossover Fund III, L.P. (7.10%)
12,254,9017.10%13G (passive)Jul 28, 2026
Vivo Opportunity, LLC11,817,4016.90%13G (passive)Jul 28, 2026
Bong Y. Koh
Joint filing with Venrock Healthcare Capital Partners III, L.P. (5.10%), VHCP Co-Investment Holdings III, LLC (5.10%) and 4 more
8,861,7635.10%13G (passive)Oct 23, 2026
Knoll Capital Management, LLC
Joint filing with Fred Knoll (15.00%), Gakasa Holdings, LLC (15.00%)
5,881,87915.00%13G (passive) amendmentNov 14, 2024
Opko Health, Inc.3,685,2268.10%13G (passive)Mar 16, 2025
Point72 Asset Management, L.P.
Joint filing with Point72 Capital Advisors, Inc. (6.80%), Steven A. Cohen (6.80%)
2,701,5606.80%13G (passive)Jan 3, 2025
Centillion Fund, Inc.2,396,9536.70%13G (passive) amendmentJul 19, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ENTXValueChange% of portfolio
Knoll Capital Management, LLC5,881,8793.40%$10.41M–5.81%
Bvf Inc/Il2,425,0001.40%$4.29MNew0.11%
Siren, L.L.C.736,4570.43%$1.30MNew0.03%
Renaissance Technologies LLC368,8470.21%$652.86K−104,5950.00%
Parkman Healthcare Partners LLC274,4970.16%$485.86K−14,1730.05%
PNC Financial Services Group, Inc.273,0310.16%$483.27K+263,0310.00%
Seven Fleet Capital Management LP191,3540.11%$338.70K−14,1880.06%
HighTower Advisors, LLC74,5730.04%$132.94K+37,7430.00%
Hrt Financial LP72,4860.04%$128.00K+56,9940.00%
Schonfeld Strategic Advisors LLC58,8710.03%$104.20K+3,6480.00%
Two Sigma Securities, LLC48,5930.03%$86.01KNew0.01%
Signature Estate & Investment Advisors LLC47,3280.03%$83.77K–0.00%
JPMorgan Chase & Co40,8830.02%$67.46K+33,7330.00%
Citadel Advisors LLC38,8040.02%$68.68K−206,7730.00%
Virtu Financial LLC36,9210.02%$65.00KNew0.00%
Geode Capital Management, LLC29,9080.02%$52.94K+8,7720.00%
Diadema Partners LP23,2600.01%$41.17K–0.01%
XTX Topco Ltd20,5590.01%$36.39K−111,0630.00%
Gem Investment Advisors, LLC19,1350.01%$33.87K–0.02%
Jane Street Group, LLC17,3310.01%$30.68K−15,5840.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20262711M6.2%7 / 86 / 64M1M
Q1 2026268M4.5%8 / 57 / 41M2M
Q4 2025229M5.4%5 / 64 / 40M0M
Q3 2025229M5.3%4 / 57 / 11M2M
Q2 20251910M5.9%4 / 53 / 30M0M
Q1 20251810M5.9%4 / 43 / 03M0M
Q4 2024147M4.3%2 / 52 / 52M0M
Q3 2024175M3.1%3 / 33 / 10M0M
Q2 2024155M3.1%5 / 23 / 51M0M
Q1 2024154M2.5%7 / 31 / 20M0M
Q4 2023104M2.3%2 / 31 / 42M0M
Q3 2023123M1.5%3 / 33 / 30M0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Miranda Jayne ToledanoChief Executive Officer, Director847,1350.49%Aug 7, 2026
Riccardo Paolo CamisascaChief Medical Officer––Aug 21, 2026
Hillel GalitzerChief Operating Officer163,5660.09%Aug 7, 2026
Gregory BurshteinChief of R&D189,0330.11%Aug 7, 2026
Dana Yaacov-GarbeliChief Financial Officer258,1720.15%Aug 7, 2026
Leslie Velka GautamChief Business Officer––May 20, 2025
Yonatan MalcaDirector100,2310.06%Aug 7, 2026
Haya TaitelDirector119,2690.07%Aug 7, 2026
Steven D. RubinDirector34,1170.02%Aug 7, 2026
Sean EllisDirector208,1320.12%Aug 7, 2026
Geno J. GermanoDirector65,0140.04%Aug 7, 2026
Gerald M. OstrovDirector75,6570.04%Jan 2, 2026
Gerald M. LiebermanDirector344,6540.20%Jan 2, 2026
Knoll Capital Management, LLC10% owner5,534,2753.20%Nov 20, 2024

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Sean Ellis
Director
Aug 7, 2026Award+20,034––208,132
Yonatan Malca
Director
Aug 7, 2026Award+22,815––100,231
Steven D. Rubin
Director
Aug 7, 2026Award+19,117––34,117
Haya Taitel
Director
Aug 7, 2026Award+20,790––119,269
Geno J. Germano
Director
Aug 7, 2026Award+25,014––65,014
Miranda Jayne Toledano
Chief Executive Officer, Director
Jul 14, 2026Award+72,993––847,135
Miranda Jayne Toledano
Chief Executive Officer, Director
Jul 14, 2026Award+347,567––774,142
Dana Yaacov-Garbeli
Chief Financial Officer
May 7, 2026Award+58,394––171,441
Gregory Burshtein
Chief of R&D
May 7, 2026Award+87,591––189,033
Hillel Galitzer
Chief Operating Officer
May 7, 2026Award+72,993––163,566
Geno J. Germano
Director
Mar 9, 2026Buy+20,000$1.30$26.00K40,000
Sean Ellis
Director
Mar 5, 2026Buy+10,000$1.23$12.30K188,098
Steven D. Rubin
Director
Feb 12, 2026Buy+5,000$1.49$7.45K15,000
Geno J. Germano
Director
Feb 10, 2026Buy+20,000$1.49$29.80K–
Haya Taitel
Director
Feb 10, 2026Buy+7,500$1.48$11.10K–
Sean Ellis
Director
Feb 9, 2026Buy+18,000$1.24$22.32K178,098
Steven D. Rubin
Director
Feb 9, 2026Buy+10,000$1.20$12.00K10,000
Haya Taitel
Director
Jan 1, 2026Award+26,329––90,979
Gerald M. Ostrov
Director
Jan 1, 2026Award+28,721––75,657
Gerald M. Lieberman
Director
Jan 1, 2026Award+38,294––338,454
Yonatan Malca
Director
Jan 1, 2026Award+30,157––77,416
Sean Ellis
Director
Jan 1, 2026Award+25,371––160,098
Miranda Jayne Toledano
Chief Executive Officer, Director
Dec 29, 2025Buy+11,000$1.81$19.91K426,575
Miranda Jayne Toledano
Chief Executive Officer, Director
Jul 16, 2025Award+136,842––371,715
Miranda Jayne Toledano
Chief Executive Officer, Director
Jul 16, 2025Award+43,860––415,575
Gregory Burshtein
Chief of R&D
Jul 16, 2025Award+26,316––101,442
Dana Yaacov-Garbeli
Chief Financial Officer
Jul 16, 2025Award+26,316––113,047
Hillel Galitzer
Chief Operating Officer
Apr 28, 2025Award+26,316––90,573
Gerald M. Lieberman
Director
Apr 1, 2025Option exercise+23,952$1.00$23.95K300,160
Gerald M. Ostrov
Director
Jan 15, 2025Award+8,038––46,936
Gerald M. Lieberman
Director
Jan 15, 2025Award+10,717––276,208
Yonatan Malca
Director
Jan 15, 2025Award+8,216––47,259
Sean Ellis
Director
Jan 15, 2025Award+7,100––134,727
Haya Taitel
Director
Jan 15, 2025Award+6,922––64,650
Haya Taitel
Director
Oct 2, 2024Award+7,278––57,728
Gerald M. Ostrov
Director
Oct 2, 2024Award+8,452––38,898
Sean Ellis
Director
Oct 2, 2024Award+7,466––127,627
Yonatan Malca
Director
Oct 2, 2024Award+8,639––39,043
Gerald M. Lieberman
Director
Oct 2, 2024Award+11,269––265,491
Gerald M. Lieberman
Director
Aug 27, 2024Award+27,261––254,222
Gerald M. Ostrov
Director
Aug 27, 2024Award+20,446––30,446
Haya Taitel
Director
Aug 27, 2024Award+15,335––50,450
Sean Ellis
Director
Aug 27, 2024Award+18,061––120,161
Yonatan Malca
Director
Aug 27, 2024Award+23,172––30,404
Miranda Jayne Toledano
Chief Executive Officer, Director
Jul 31, 2024Award+124,121––234,873
Dana Yaacov-Garbeli
Chief Financial Officer
Apr 19, 2024Award+30,151––86,731
Hillel Galitzer
Chief Operating Officer
Apr 19, 2024Award+30,151––64,257
Dana Yaacov-Garbeli
Chief Financial Officer
Apr 19, 2024Award+30,151––86,731
Haya Taitel
Director
Jan 12, 2024Buy+9,500$0.99$9.41K35,115
Haya Taitel
Director
Jan 10, 2024Buy+7,615$0.77$5.86K25,615
Gerald M. Lieberman
Director
Dec 22, 2023Buy+23,952$0.71$17.01K226,961
Miranda Jayne Toledano
Chief Executive Officer, Director
Dec 22, 2023Buy+23,952$0.71$17.01K110,752
Haya Taitel
Director
Aug 22, 2023Buy+18,000$0.62$11.16K18,000
Gerald M. Lieberman
Director
Aug 21, 2023Buy+20,000$0.59$11.80K214,209
Sean Ellis
Director
Aug 21, 2023Buy+40,000$0.60$24.00K102,100
Miranda Jayne Toledano
Chief Executive Officer, Director
Apr 4, 2023Buy+30,000$1.01$30.30K86,800
Dana Yaacov-Garbeli
Chief Financial Officer
Nov 14, 2022Buy+26,580$0.54$14.35K56,580
Gerald M. Lieberman
Director
Nov 14, 2022Buy+34,000$0.57$19.38K194,209
Gerald M. Lieberman
Director
Nov 14, 2022Buy+4,000$0.56$2.24K6,200
Gerald M. Lieberman
Director
Nov 14, 2022Buy+4,000$0.56$2.24K6,200

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
4.61%
7M shares short
Days to cover
15.6
At 0M shares a day
Change since last report
+27.4%
From 6M shares
Short volume, 20 days
64.0%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Entera Bio's stock actually held short. Settlement fails (shares not delivered on time) peaked at 133,414 shares on Oct 13, 2026 over the last 90 days.

See a number that looks wrong?